Back to all papers

Automated Measurement of Depigmentation Extent with a New AI Tool Applied to the Example of Vitiligo.

May 4, 2026pubmed logopapers

Authors

Chen Y,Lukic T,Chen AS,Adiri R,Tran H,Schaefer G,Ghosh P,Madhavan S,Soma K,Gamalo M

Affiliations (6)

  • Pfizer Inc., Cambridge, MA, USA. [email protected].
  • Pfizer Inc., New York, NY, USA.
  • Pfizer Inc., Groton, CT, USA.
  • Pfizer Pharmaceuticals Ltd, Herzliya Pituach, Israel.
  • Pfizer Inc., Cambridge, MA, USA.
  • Pfizer Pharma GmbH, Berlin, Germany.

Abstract

We have developed a digital algorithm to assess skin pigmentation, specifically an artificial intelligence-based image analysis tool that segments photographed lesions and then scores them by Facial Vitiligo Area Scoring Index (F-VASI), in place of trained site investigators. Vitiligo, the disease used in this exemplary demonstration of the algorithm, is a chronic, acquired, immune-mediated depigmentation disease characterized by white macules and/or patches of skin. The F-VASI is a clinician-reported outcome that relies on manual assessment of affected body surface area (BSA) and level of depigmentation and is subject to inter- and intra-rater variability. Here, we present automated medical image segmentation of vitiligo lesions and digitization of validated scores, including F-VASI, BSA, and percentage of depigmentation (%Depigmentation). Our convolutional neural network ("UNet") uses encoder-decoder architecture to process photographic images and quantify areas of skin affected by vitiligo. We trained and validated our model using cross-polarized participant photos from clinical trials, achieving 81% accuracy when predicting vitiligo lesions in new photos. In addition, we created an algorithm to digitize F-VASI assessment using estimates of BSA and %Depigmentation that were calculated using the predicted lesions in the photos. We were able to achieve an interclass correlation coefficient of 0.91 when comparing our digital F-VASI score to the manually estimated F-VASI score. We found that using a UNet to segment vitiligo lesions can allow us to digitize clinically meaningful measures for vitiligo. The phase 2b study: NCT03715829.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.